Back to top
more

Inari Medical (NARI)

(Delayed Data from NSDQ)

$49.65 USD

49.65
574,532

+2.12 (4.46%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $49.66 +0.01 (0.02%) 4:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Indrajit Bandyopadhyay headshot

Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More

Medical Device companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, QDEL, GKOS and NARI are placed ahead of their earnings release.

Zacks Industry Outlook Highlights Alcon, STERIS and Inari Medical

Alcon, STERIS and Inari Medical are part of the Zacks Industry Outlook article.

Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View

The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.

Urmimala Biswas headshot

3 Medical Instruments Stocks Countering Industry-Wide Headwinds

The Zacks Medical - Instruments industry is being affected by ongoing inflation and a tightening monetary policy. However, the rising demand for digital health offers some respite. ALC, STE and NARI are poised to brave the challenges.

Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise

Chemed's (CHE) third-quarter 2023 performance reflects strength in the VITAS segment.

ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Down

ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.

Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter.

Edwards Lifesciences (EW) Q3 Earnings Match Mark, Margins Dip

Edwards Lifesciences (EW) TMTT performance benefits from the accelerated adoption of the differentiated PASCAL precision platform in the third quarter.

Labcorp (LH) Q3 Earnings and Revenues Beat, Margins Fall

Labcorp (LH) delivers a strong performance in the third quarter of 2023 across the Diagnostics Laboratories and Biopharma Laboratory Services businesses.

Integra's (IART) Q3 Earnings Miss Estimates, 2023 View Cut

The impact of lost revenues and an increase in the return provision related to the Boston product recall dent Integra's (IART) Q3 revenues.

Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q3 performance.

Align Technology (ALGN) Q3 Earnings Miss, Operating Margin Up

Align Technology's (ALGN) Q3 fiscal 2023 performance reflects revenue growth across all regions.

Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Up

Thermo Fisher's (TMO) PPI Business System and strong execution by its global team enabled the company to deliver strong financial performance for Q3.

Quest Diagnostics (DGX) Tops Q3 Earnings, Gross Margin Dips

Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.

Tirthankar Chakraborty headshot

3 Solid Stocks to Buy for Superb Earnings Acceleration

Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.

Reasons to Add Inari Medical (NARI) Stock to Your Portfolio

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Tirthankar Chakraborty headshot

4 Stocks That Exhibit Solid Earnings Acceleration

Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.

Wall Street Analysts See a 36.39% Upside in Inari Medical, Inc. (NARI): Can the Stock Really Move This High?

The consensus price target hints at a 36.4% upside potential for Inari Medical, Inc. (NARI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Shockwave Medical (SWAV) Q2 Earnings Miss, Revenues Surge Y/Y

Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y

Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.

Inari Medical, Inc. (NARI) Tops Q2 Earnings and Revenue Estimates

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 128.57% and 2.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Add Inari Medical (NARI) Stock to Your Portfolio

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Inari Medical (NARI) Launches New Catheters to Address VTE

Inari Medical's (NARI) latest launches are expected to serve a wider patient pool by improving treatment options.

Inari Medical, Inc. (NARI) Down 0.6% Since Last Earnings Report: Can It Rebound?

Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.